Stockhub

Editing Johnson & Johnson

Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.

The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.

Latest revision Your text
Line 302: Line 302:


Here, to estimate the adjusted beta, we used the iShares MSCI World ETF to represent the market portfolio; and in terms of the time period and frequency of observations, we used five years of monthly data (i.e. 60 observations in total), which is supported by a study and is the most common choice. The beta value in a future period has been found to be on average closer to the mean value of 1.0, and because valuation is forward-looking, it is logical to adjust the raw beta so it more/most accurately predicts a future beta. In addition, here, we have assumed that for an investment to be considered 'medium' risk, it must have a beta value of between 0.5 and 1.5. Further information about the beta ratings can be found in the appendix section of this report.
Here, to estimate the adjusted beta, we used the iShares MSCI World ETF to represent the market portfolio; and in terms of the time period and frequency of observations, we used five years of monthly data (i.e. 60 observations in total), which is supported by a study and is the most common choice. The beta value in a future period has been found to be on average closer to the mean value of 1.0, and because valuation is forward-looking, it is logical to adjust the raw beta so it more/most accurately predicts a future beta. In addition, here, we have assumed that for an investment to be considered 'medium' risk, it must have a beta value of between 0.5 and 1.5. Further information about the beta ratings can be found in the appendix section of this report.
==== Risks that Johnson & Johnson is exposed to: ====
Risks Related to Our Business, Industry and Operations:
* The Company’s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company’s earnings.
* Interruptions and delays in manufacturing operations could adversely affect the Company’s business, sales and reputation
* The Company relies on third parties to manufacture certain of our products. Any failure by or loss of a third party manufacturer could result in delays and increased costs, which may adversely affect our business.
* Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business.
* Global health crises, pandemics, epidemics, or other outbreaks could adversely disrupt or impact certain aspects of the Company’s business, results of operations and financial condition
Risks Related to Government Regulation and Legal Proceedings:
* Global sales in the Company’s Pharmaceutical and MedTech segments may be negatively impacted by healthcare reforms and increasing pricing pressures
* The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.
* The Company faces significant regulatory scrutiny, which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties
* Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company’s operating results.
Risks Related to Our Intellectual Property
* The Company faces increased challenges to intellectual property rights central to its business.
Risks Related to Product Development, Regulatory Approval and Commercialization
* Significant challenges or delays in the Company’s innovation and development of new products, technologies and indications could have an adverse impact on the Company’s long-term success
Risks Related to Financial and Economic Market Conditions:
* The Company faces a variety of financial, economic, legal, social and political risks associated with conducting business internationally.
* Failure to maintain a satisfactory credit rating could adversely affect our liquidity, capital position, borrowing costs and access to capital markets
* The Russia-Ukraine War, and actions taken in response to the Russia-Ukraine War, could adversely affect our business, results of operations or financial condition.


== Financials ==
== Financials ==
 
ccc
=== Income Statement ===
{| class="wikitable"
|-
!'''USDm'''
!'''2020'''
!'''2021'''
!'''2022'''
!'''2023E'''
!'''2024E'''
!'''2025E'''
!'''2026E'''
!'''2027E'''
|-
|Assumptions:
|
|
|
|
|
|
|
|
|-
|'''Revenue growth'''
| -
|14%
|1%
|7.5%
|7.5%
|7.5%
|7.5%
|7.5%
|-
|'''Cost of sales % revenues'''
| -
|5%
|4%
|4.5%
|4.5%
|4.5%
|4.5%
|4.5%
|-
|'''Research and Development as % gross  profit'''
| -
|21%
| -1%
|9.9%
|9.9%
|9.9%
|9.9%
|9.9%
|-
|'''General and administrative expenses %  gross profit'''
| -
|12%
|0%
|6.2%
|6.2%
|6.2%
|6.2%
|6.2%
|-
|'''Other operating income as % of gross  profit'''
| -
|300%
| -13%
|143.5%
|143.5%
|143.5%
|143.5%
|143.5%
|-
|'''Pretax Income %'''
| -
|43%
| -9%
|17.2%
|17.2%
|17.2%
|17.2%
|17.2%
|-
|'''Taxes % of profit before tax'''
| -
|6%
|99%
|52.7%
|52.7%
|52.7%
|52.7%
|52.7%
|-
|'''% basic net earning per share'''
|
|42%
| -14%
|14%
|14.0%
|14.0%
|14.0%
|14.0%
|-
|'''% diluted net earning per  share'''
|
|42%
| -14%
|14%
|14%
|14%
|14%
|14%
|-
|'''% average share outstanding  basic'''
|
|0%
|0%
|0%
|0%
|0%
|0%
|0%
|-
|'''% average share outstanding  diluted'''
|
|0%
|0%
|0%
|0%
|0%
|0%
|0%
|-
|
|
|
|
|
|
|
|
|
|-
|'''Total Revenue'''
|                     82,584
|                     93,775
|              94,943
|           102,064
|           109,719
|           117,947
|           126,793
|           136,303
|-
|'''Cost of Sales'''
|                   (28,427)
|                   (29,855)
|            (31,089)
|              (4,593)
|              (4,937)
|              (5,308)
|              (5,706)
|              (6,134)
|-
|'''Gross Profit'''
|                     54,157
|                     63,920
|              63,854
|              97,471
|           104,781
|           112,640
|           121,088
|           130,169
|-
|
|
|
|
|
|
|
|
|
|-
|'''Operating Expenses'''
|                   (34,243)
|                   (39,373)
|            (39,368)
|           124,132
|           133,442
|           143,450
|           154,209
|           165,775
|-
|'''Research & Development'''
|                   (12,159)
|                   (14,714)
|            (14,603)
|              (9,681)
|            (10,407)
|            (11,187)
|            (12,026)
|            (12,928)
|-
|'''Selling, General &  Administrative'''
|                   (22,084)
|                   (24,659)
|            (24,765)
|              (6,058)
|              (6,512)
|              (7,001)
|              (7,526)
|              (8,090)
|-
|'''Other Operating Income  (Expenses)'''
|                         (181)
|                         (900)
|                 (783)
|            139,871
|            150,361
|            161,638
|            173,761
|            186,793
|-
|
|
|
|
|
|
|
|
|
|-
|'''Operating Income'''
|                     19,914
|                     24,547
|              24,486
|           221,603
|           238,223
|           256,090
|           275,297
|           295,944
|-
|'''Interest Income'''
|                         (111)
|                           (53)
|                 (490)
|
|
|
|
|
|-
|'''Interest expense, net of  portion capitalised'''
|                         (210)
|                         (183)
|                 (276)
|
|
|
|
|
|-
|'''Other Income/Expenses Net'''
|                     (2,899)
|                         (489)
|              (1,871)
|
|
|
|
|
|-
|'''Restructuring'''
|                         (247)
|                         (252)
|                 (321)
|
|
|
|
|
|-
|
|
|
|
|
|
|
|
|
|-
|'''Pretax Income'''
|                     16,447
|                     23,570
|              21,528
|              25,220
|              29,545
|              34,612
|              40,548
|              47,502
|-
|'''Tax Provision'''
|                     (1,783)
|                     (1,898)
|              (3,784)
|            (13,291)
|            (15,570)
|            (18,241)
|            (21,369)
|            (25,034)
|-
|'''Net Income from Continuing  Operations'''
|                     14,664
|                     21,672
|              17,744
|              11,929
|              13,975
|              16,372
|              19,179
|              22,469
|-
|
|
|
|
|
|
|
|
|
|-
|'''Gross profit margin %'''
|65.6%
|68.2%
|67.3%
|95.5%
|95.5%
|95.5%
|95.5%
|95.5%
|-
|'''Operating profit margin %'''
|24.1%
|26.2%
|25.8%
|217.1%
|217.1%
|217.1%
|217.1%
|217.1%
|-
|'''Net profit margin %'''
|17.8%
|23.1%
|18.7%
|11.7%
|12.7%
|13.9%
|15.1%
|16.5%
|-
|
|
|
|
|
|
|
|
|
|-
|'''Net  Earning per Share'''
|
|
|
|
|
|
|
|
|-
|'''Basic'''
|                         5.59
|                         7.93
|                  6.83
|                  7.79
|                  8.88
|                10.12
|                11.54
|                13.15
|-
|'''Diluted'''
|                         5.51
|                         7.81
|                  6.73
|                  7.67
|                  8.75
|                  9.97
|                11.37
|                12.96
|-
|
|
|
|
|
|
|
|
|
|-
|'''Average  Shares Outstanding'''
|
|
|
|
|
|
|
|
|-
|'''Basic'''
|                 2,632.80
|                 2,632.10
|          2,625.20
|          2,618.35
|          2,626.20
|          2,619.34
|          2,627.20
|          2,620.33
|-
|'''Diluted'''
|                 2,663.90
|                 2,674.00
|          2,670.70
|          2,663.73
|          2,656.76
|          2,649.82
|          2,642.90
|          2,635.99
|}
 
=== Cash Flow ===
{| class="wikitable"
|-
!'''USDm'''
!2020
!2021
!2022
!2023E
!2024E
!2025E
!2026E
!2027E
|-
|'''Assumptions'''
|
|
|
|
|
|
|
|
|-
|'''D&A as % of prior year  long term assets'''
| -
|2%
| -6%
| -1.7%
| -1.7%
| -1.7%
| -1.7%
| -1.7%
|-
|'''Stock based compensation %  growth'''
| -
|7%
|75%
|41.0%
|41.0%
|41.0%
|41.0%
|41.0%
|-
|'''Common stock repurchased %  growth'''
| -
| -7%
|28%
|10.5%
|10.5%
|10.5%
|10.5%
|10.5%
|-
|'''Dividend payout ratio'''
| -
|5%
|6%
|5.6%
|5.6%
|5.6%
|5.6%
|5.6%
|-
|
|
|
|
|
|
|
|
|
|-
|
|
|
|
|
|
|
|
|
|-
|'''Cash Flows from operating  activities'''
|
|
|
|
|
|
|
|
|-
| '''Net Income from Continuing Operations'''
|               14,714
|                20,878
|              17,941
|             11,929
|                   13,975
|                   16,372
|                   19,179
|                   22,469
|-
| '''Depreciation & Amortization'''
|                  7,231
|                  7,390
|                6,970
|              (2,298)
|                   (2,398)
|                   (2,505)
|                   (2,621)
|                   (2,746)
|-
| '''Asset write-downs'''
|                     233
|                     989
|                1,216
|                   813
|                       813
|                       958
|                       950
|                       883
|-
| '''Stock based compensation'''
|                  1,005
|                  1,135
|                1,138
|               1,605
|                     2,262
|                     3,190
|                     4,498
|                     6,342
|-
| '''Provision & Write off of Assets'''
|                       63
|                       (48)
|                     (17)
|                       -  
|                           -  
|                           -  
|                           -  
|                           -  
|-
| '''Operating Gains Losses'''
|                   (111)
|                     (617)
|                 (380)
|              (1,837)
|                     (833)
|                     (952)
|                   (1,083)
|                   (1,226)
|-
| '''Deferred Tax provision'''
|                (1,141)
|                (2,079)
|              (1,663)
|
|
|
|
|
|-
| '''Other non-cash items'''
|                (1,148)
| -
| -
|
|
|
|
|
|-
| '''Change in working capital'''
|                  2,690
|                (4,238)
|              (4,011)
|
|
|
|
|
|-
| '''Operating Cash Flow'''
|               23,536
|                23,410
|              21,194
|             10,211
|                 13,819
|                 17,062
|                 20,923
|                 25,722
|-
|
|
|
|
|
|
|
|
|
|-
| '''Cash Flows from investing activities'''
|
|
|
|
|
|
|
|
|-
| '''Investments in property, plant and  equipment'''
|                (3,347)
|                (3,652)
|              (4,009)
|                   535
|                       549
|                       564
|                       579
|                       595
|-
| '''Business Acquisitions, net'''
|                (7,323)
|                       (60)
|            (17,652)
|              (2,620)
|                           -  
|                           -  
|                           -  
|                           -  
|-
| '''Purchases of investments'''
|                (8,952)
|                (5,388)
|                9,225
|              (2,565)
|                   (2,917)
|                   (3,316)
|                   (3,771)
|                   (4,287)
|-
| '''Other investing activities'''
|                (1,203)
|                     417
|                     65
|
|
|
|
|
|-
| '''Investing Cash Flow'''
|              (20,825)
|                (8,683)
|            (12,371)
|              (4,650)
|                   (2,368)
|                   (2,752)
|                   (3,192)
|                   (3,692)
|-
| '''Other investing activities'''
|                         -  
|                       (11)
|                         1
|                       -  
|                           -  
|                           -  
|                           -  
|                           -  
|-
| '''Cash Flows from financing activities'''
|
|
|
|
|
|
|
|
|-
| '''Debt repayment (increase in debt)'''
|                  7,095
|                     (990)
|                7,452
|              (6,000)
|                   (5,307)
|                   (4,829)
|                   (4,395)
|                   (3,999)
|-
| '''Common stock issued'''
|                (3,221)
|                (3,456)
|              (6,035)
|              (8,509)
|                 (11,998)
|                 (16,917)
|                 (23,854)
|                 (33,634)
|-
| '''Common stock repurchased'''
|                  1,114
|                  1,036
|                1,329
|               1,469
|                     1,623
|                     1,793
|                     1,981
|                     2,189
|-
| '''Dividends paid'''
|              (10,481)
|              (11,032)
|            (11,682)
|                 (667)
|                     (782)
|                     (916)
|                   (1,073)
|                   (1,257)
|-
| '''Other financing activities'''
|                   (627)
|                     395
|                     65
|                       -  
|                           -  
|                           -  
|                           -  
|                           -  
|-
| '''Financing Cash Flow'''
|                (6,120)
|              (14,047)
|              (8,871)
|           (13,708)
|                 (16,464)
|                 (20,870)
|                 (27,340)
|                 (36,701)
|-
|
|
|
|
|
|
|
|
|
|-
| '''Cash'''
|
|
|
|
|
|
|
|
|-
| '''Net change in cash'''
|               17,238
|                  9,304
|                7,329
|           (12,798)
|                   (7,381)
|                   (9,313)
|                 (12,800)
|                 (18,363)
|-
| '''Cash at beginning of period'''
| -
|                17,238
|              26,542
|             33,871
|                   21,073
|                   13,692
|                     4,380
|                   (8,420)
|-
| '''Cash at end of period'''
|               17,238
|                26,542
|              33,871
|             21,073
|                   13,692
|                     4,380
|                   (8,420)
|                 (26,783)
|}
 
=== Balance Sheet ===
{| class="wikitable"
|-
!'''USDm'''
!2020
!2021
!2022
!2023E
!2024E
!2025E
!2026E
!2027E
|-
|'''Cash and Short Term  Investments'''
| -0.5%
|25.0%
| -26%
| -0.3%
|
|
|
|
|-
|'''Accounts Receivable % Revenues'''
| -
|13%
|26%
|19.3%
|19.3%
|19.3%
|19.3%
|19.3%
|-
|'''Inventory % Revenue'''
| -
|11%
|20%
|15.6%
|15.6%
|15.6%
|15.6%
|15.6%
|-
|'''Other Current Assets'''
| -
|18.0%
| -
|18.0%
|18.0%
|18.0%
|18.0%
|18.0%
|-
|'''Net Property, Plant &  Equipment (PPE)'''
| -
|1%
|4%
|2.7%
|2.7%
|2.7%
|2.7%
|2.7%
|-
|'''Other Non-Current Assets'''
| -
|35%
| -8%
|13.7%
|13.7%
|13.7%
|13.7%
|13.7%
|-
|'''Goodwill'''
| -
| -9%
|15%
|2.8%
|2.8%
|2.8%
|2.8%
|2.8%
|-
|'''Accounts Payable % COGS'''
| -
|4%
|5%
|4.4%
|4.4%
|4.4%
|4.4%
|4.4%
|-
|'''Other Current Liabilities'''
| -
|3%
| -7%
| -2.1%
| -2.1%
| -2.1%
| -2.1%
| -2.1%
|-
|'''Short term debt % LT debt'''
| -
|43%
|239%
|141.0%
|141.0%
|141.0%
|141.0%
|141.0%
|-
|'''Long Term Debt'''
| -
| -8%
| -10%
| -9.0%
| -9.0%
| -9.0%
| -9.0%
| -9.0%
|-
|'''Other Non-Current Liabilities'''
| -
| -10%
| -15%
| -12.5%
| -12.5%
| -12.5%
| -12.5%
| -12.5%
|-
|
|
|
|
|
|
|
|
|
|-
|'''Cash and Short Term  Investments'''
|                     25,186
|               31,608
|                   23,519
|                   23,401
|             23,284
|             23,168
|             23,052
|             22,937
|-
|'''Accounts Receivable'''
|                     13,576
|               15,283
|                   19,292
|                   19,647
|             21,121
|             22,705
|             24,408
|             26,238
|-
|'''Inventory'''
|                       9,344
|               10,387
|                   12,483
|                   15,871
|             17,061
|             18,341
|             19,716
|             21,195
|-
|'''Other Current Assets'''
|                       3,132
|                 3,701
| -
|                           -  
|                       -  
|                       -  
|                       -  
|                       -  
|-
|'''Total Current Assets'''
|                     51,238
|              60,979
|                 55,294
|                 58,920
|             61,466
|             64,214
|             67,176
|             70,370
|-
|'''Net Property, Plant &  Equipment (PPE)'''
|                     18,766
|               18,962
|                   19,803
|                   20,338
|             20,887
|             21,451
|             22,030
|             22,625
|-
|'''Other Non-Current Assets'''
|                     15,097
|               20,439
|                   18,725
|                   21,290
|             24,207
|             27,523
|             31,294
|             35,581
|-
|'''Goodwill'''
|                     89,795
|               81,638
|                   93,556
|                   96,176
|             98,868
|           101,637
|           104,483
|           107,408
|-
|'''Total Non-Current Assets'''
|                   123,658
|            121,039
|               132,084
|               137,804
|           143,962
|           150,611
|           157,807
|           165,614
|-
|'''Total Assets'''
|                   174,896
|            182,018
|               187,378
|               196,723
|           205,429
|           214,825
|           224,983
|           235,985
|-
|
|
|
|
|
|
|
|
|
|-
|'''Accounts Payable'''
|                     36,378
|               37,874
|                   39,703
|                   41,609
|             43,440
|             45,351
|             47,346
|             49,430
|-
|'''Other Current Liabilities'''
|                       3,484
|                 3,586
|                     3,328
|                     3,260
|               3,193
|               3,127
|               3,063
|               3,001
|-
|'''Short term debt'''
|                       2,631
|                 3,766
|                   12,771
|                   34,500
|             31,395
|             28,569
|             25,998
|             23,658
|-
|'''Total Current Liabilities'''
|                     42,493
|              45,226
|                 55,802
|                 79,369
|             78,027
|             77,048
|             76,408
|             76,088
|-
|'''Long Term Debt'''
|                     32,635
|               29,985
|                   26,888
|                   24,468
|             22,266
|             20,262
|             18,438
|             16,779
|-
|'''Other Non-Current Liabilities'''
|                     36,488
|               32,784
|                   27,884
|                   24,399
|             21,349
|             18,680
|             16,345
|             14,302
|-
|'''Total Non-Current Liabilities'''
|                     69,123
|              62,769
|                 54,772
|                 48,867
|             43,615
|             38,942
|             34,784
|             31,081
|-
|'''Total Liabilities'''
|                   111,616
|            107,995
|               110,574
|               128,235
|           121,642
|           115,990
|           111,191
|           107,169
|-
|
|
|
|
|
|
|
|
|
|-
|'''Common Stock Equity'''
|                     63,278
|              74,023
|                 76,804
|                 68,488
|             83,787
|             98,835
|           113,792
|           128,815
|-
|'''Noncontrolling interests in  subsidiaries'''
|                               -  
|                       -  
|                           -  
|
|
|
|
|
|-
|'''Equity + Liabilities'''
|                   174,896
|            182,018
|               187,378
|               196,723
|           205,429
|           214,825
|           224,983
|           235,985
|}
 
== Valuation ==
== Valuation ==


Line 1,552: Line 310:


==== What's the expected return of an investment in the company? ====
==== What's the expected return of an investment in the company? ====
The Stockhub users estimate that the expected return of an investment in the company over the next five years is negative 22.83%, which equates to an annual return of negative 4.96%. In other words, an £1,000 investment in the company is expected to return £774 in five years time. The assumptions used to estimate the return figure can be found in the table below.
The Stockhub users estimate that the expected return of an investment in the company over the next five years is negative 22.83%, which equates to an annual return of negative 72.63%. In other words, an £1,000 investment in the company is expected to return £ccc in five years time. The assumptions used to estimate the return figure can be found in the table below.


Assuming that a suitable return level over five years is negative 4.96% per year or less, and Johnson & Johnson achieves its expected return level (of negative 4.96%), then an investment in the company is considered to be an 'suitable' one.
Assuming that a suitable return level over five years is ccc% per year or less, and Johnson & Johnson achieves its expected return level (of ccc%), then an investment in the company is considered to be an 'suitable' one.


==== What are the assumptions used to estimate the return? ====
==== What are the assumptions used to estimate the return? ====
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see Stockhub:Copyrights for details). Do not submit copyrighted work without permission!
Cancel Editing help (opens in new window)

Templates used on this page:

Retrieved from ‘https://stockhub.co/research/Johnson_%26_Johnson’